Ligand ID: TOY


Drugbank ID:
DB00684
(Tobramycin)


Indication:
For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.

Get human targets for TOY in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'TOY'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		1x7q HLA, A-11
(Homo
sapiens)		4 / 8
TYR A  85
ASP A 137
ILE A  95
ASP A 119
1.60A22.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		1x7q HLA, A-11
(Homo
sapiens)		4 / 8
TYR A  85
ASP A 137
ILE A  95
ASP A 119
1.57A22.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2dd8 IGG HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
ASP H 101
ILE H  34
ASP H  95
TYR S 491
1.37A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		2dd8 IGG HEAVY CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
ASP H 101
ILE H  34
ASP H  95
TYR S 491
1.46A19.20
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2dd8 IGG LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
ASP L  95
TYR S 491
ASP S 393
TYR S 481
1.67A20.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		2fe8 REPLICASE
POLYPROTEIN 1AB
(SARSr-CoV)		5 / 10
PHE B  70
SER A  86
ALA A  87
THR A 159
ASP B  77
1.70A20.52
None
BR  A 319 (-3.4A)
BR  A 319 (-4.0A)
BR  A 319 ( 4.5A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 9
ASP C 393
SER D 101
ALA C 430
THR C 487
ASP C 392
1.74A20.18
None
None
None
None
CL  C  20 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		2ghw ANTI-SCFV ANTIBODY,
80R
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		5 / 10
ASP C 393
SER D 101
ALA C 430
THR C 487
ASP C 392
1.73A20.18
None
None
None
None
CL  C  20 ( 4.9A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		2gri NSP3
(SARSr)		4 / 8
ASP A  29
ASP A  33
GLU A  27
TYR A 108
1.35A18.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		4 / 8
ASP A 272
ASP A  87
ILE A 269
ASP A 267
1.56A19.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		2h85 PUTATIVE ORF1AB
POLYPROTEIN
(SARSr-CoV)		4 / 8
ASP A 272
ASP A  87
ILE A 269
ASP A 267
1.62A19.61
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ASP A 199
ASP A 202
ILE A 252
ASP A 296
1.43A19.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ASP B 199
GLU B  68
ILE B  71
ASP B 272
1.52A19.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ASP B 272
ASP B  87
ILE B 269
ASP B 267
1.59A19.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ASP D 199
GLU D  68
ILE D  71
ASP D 272
1.54A19.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
PHE A 149
SER A 129
ALA A 168
ASP A  97
ASP A  99
1.72A20.13
SAH  A1293 (-4.6A)
None
None
None
SAH  A1293 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2xyq PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 8
TYR A 222
ASP A 144
ILE A 229
TYR A 181
1.50A21.66
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		2xyr PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
PHE A 149
SER A 129
ALA A 168
ASP A  97
ASP A  99
1.71A20.13
SFG  A1298 ( 4.9A)
None
None
None
SFG  A1298 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 8
TYR A 222
ASP A 144
ILE A 229
TYR A 181
1.41A21.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
ASN A 177
GLU A 147
ASP A 114
GLY A 155
ASP A 179
1.78A20.49
None
None
SAH  A1300 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		2xyv PUTATIVE 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 8
TYR A 222
ASP A 144
ILE A 229
TYR A 181
1.44A21.51
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 8
ASP S 480
ASP A 480
TYR A 338
ILE A 405
1.30A17.82
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		3bgf F26G19 FAB
SPIKE PROTEIN S1
(Mus
musculus;
SARSr-CoV)		4 / 8
ASP H  56
TYR L  94
GLU H  95
TYR S 491
1.47A18.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		3bgf F26G19 FAB
SPIKE PROTEIN S1
(Mus
musculus;
SARSr-CoV)		4 / 8
ASP H  56
TYR L  94
GLU H  95
TYR S 491
1.54A18.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		3d0h ACE2
(Paguma
larvata;
Homo
sapiens;
SARSr-CoV)		5 / 9
ILE A 468
VAL A 485
TYR A 237
GLU A 467
GLU A 227
1.79A21.78
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		3eaj 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
ASP A 248
ASP A 245
ILE B 200
ASP B 197
1.58A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		3eaj 3C-LIKE PROTEINASE
(SARSr-CoV)		4 / 8
ASP A 248
ASP A 245
ILE B 200
ASP B 197
1.62A19.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		3i6g HLA, A-2
(Homo
sapiens)		4 / 8
ASP A  29
ASP A  30
ASP A 102
TYR A 113
1.62A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		3i6k BETA-2-MICROGLOBULIN
HLA, A-2
(Homo
sapiens)		4 / 8
ASP E  39
ASP E  37
GLU E  46
ASP F  53
1.64A21.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		4 / 8
ASP D  39
ASP D  37
GLU D  46
ASP E  53
1.63A21.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		3i6l BETA-2-MICROGLOBULIN
HLA, A-24
(Homo
sapiens)		4 / 8
ASP D  39
ASP D  37
GLU D  46
ASP E  53
1.62A21.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 8
TYR A 222
ASP A 144
ILE A 229
TYR A 181
1.43A18.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
PHE A 149
SER A 129
ALA A 168
ASP A  97
ASP A  99
1.71A19.83
SAM  A 302 ( 4.8A)
None
None
None
SAM  A 302 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		4 / 8
TYR A 222
ASP A 144
ILE A 229
TYR A 181
1.39A18.86
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		3r24 2'-O-METHYL
TRANSFERASE
(SARSr-CoV)		5 / 10
ASN A 177
GLU A 147
ASP A 114
GLY A 155
ASP A 179
1.68A19.08
None
None
SAM  A 302 (-3.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		3scj ACE2
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARSr-CoV)		4 / 8
ASP A  30
TYR E 440
ASP A  38
TYR E 436
1.53A14.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		5nfy POLYPROTEIN 1AB
(SARS-COV
Frankfurt
1)		5 / 9
ASP C 211
SER A 218
SER A 221
ASP A 234
THR A 219
1.65A15.82
None
PEG  C 604 ( 4.0A)
PEG  C 604 ( 4.4A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		5wrg SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 10
ASP A 757
SER A 717
ALA A 714
ASP C 600
THR A 841
1.77A9.21
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x4r S PROTEIN
(MERS-CoV)		5 / 9
ASP A 248
ILE A 245
SER A 267
VAL A 271
TYR A 332
1.53A18.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		5x4s SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
TYR A 195
ASP A 191
ASP A  57
TYR A  41
1.65A17.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 9
GLU B 452
SER C 105
SER C 113
THR C 106
ASP B 454
1.66A9.17
NAG  C1310 ( 4.3A)
NAG  C1310 ( 4.5A)
None
NAG  C1310 (-4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
ASP A 415
TYR B 195
ASP B  57
TYR B  41
1.49A10.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
ASP A 415
TYR B 195
ASP B  57
TYR B  41
1.47A10.64
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		5x58 SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		5 / 10
GLU B 452
SER C 105
SER C 113
THR C 106
ASP B 454
1.71A9.17
NAG  C1310 ( 4.3A)
NAG  C1310 ( 4.5A)
None
NAG  C1310 (-4.3A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		5x59 S PROTEIN
(MERS-CoV)		5 / 10
PHE B 865
GLU B 875
SER B 950
SER B 859
ALA B 969
1.73A9.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		5x5f S PROTEIN
(MERS-CoV)		5 / 9
ASP A 248
ILE A 245
SER A 267
VAL A 271
TYR A 332
1.53A15.23
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
ASP A 454
GLU A 452
SER C 105
SER C 111
THR C 106
1.79A9.21
ASP  A 454 ( 0.6A)
GLU  A 452 ( 0.5A)
SER  C 105 ( 0.0A)
SER  C 111 ( 0.0A)
THR  C 106 ( 0.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP B 554
ASP B 560
ILE A  46
TYR A 266
1.41A10.43
ASP  B 554 ( 0.5A)
ASP  B 560 ( 0.5A)
ILE  A  46 ( 0.7A)
TYR  A 266 ( 1.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
TYR C  41
ASP C  57
ILE C 272
ASP C  44
1.10A10.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
TYR C  41
ASP C  57
ILE C 272
ASP C  44
1.12A10.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_A_TOYA201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6ack SPIKE GLYCOPROTEIN
(SARSr-CoV)		5 / 9
ARG C 183
TRP C 101
GLU C  93
GLY C 100
ASN C  78
1.64A8.58
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
3SG8_A_TOYA305_1
(APH(2'')-ID)		6ack ACE2
(Homo
sapiens)		5 / 12
ASN D 188
SER D 511
ASP D 509
GLU D 457
TRP D 459
1.54A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
ASP B  57
TYR B 197
ILE B 272
ASP B  44
1.46A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6crv SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
ASP C 554
ASP C 560
ILE A  46
TYR A 266
1.48A8.97
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 9
GLU A 452
SER B 105
SER B 113
THR B 106
ASP A 454
1.49A9.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		5 / 10
GLU A 452
SER B 105
SER B 113
THR B 106
ASP A 454
1.50A9.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
TYR A  41
ASP A  57
ILE A 272
ASP A  44
1.23A9.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6crx SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
TYR A  41
ASP A  57
ILE A 272
ASP A  44
1.21A9.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens;
SARSr-CoV)		4 / 8
ASP B  53
GLU C   2
ILE A  66
TYR A  74
1.51A18.44
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		5 / 9
ASP B  53
ILE A  23
SER A  67
TYR A  59
GLU A  46
1.64A10.75
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6iex BETA-2-MICROGLOBULIN
MHC CLASS I ANTIGEN
(Homo
sapiens)		4 / 8
ASP A  39
ASP A  37
GLU A  46
ASP B  53
1.66A19.93
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6jyt HELICASE
(SARSr-CoV)		4 / 8
ASP B 113
ASP B 119
ASP A 119
TYR A 120
1.37A15.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6jyt HELICASE
(SARSr-CoV)		4 / 8
ASP B 113
ASP B 119
ASP A 119
TYR A 120
1.34A15.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m17 ACE2
(Homo
sapiens)		4 / 8
ASP D 367
ASP D 368
GLU D 375
ILE D 358
1.39A12.15
None
None
ZN  D 914 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6m17 ACE2
(Homo
sapiens)		4 / 8
ASP D 367
ASP D 368
GLU D 375
ILE D 358
1.38A12.15
None
None
ZN  D 914 (-4.2A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m18 SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		4 / 8
ASP C 189
TYR C 480
ILE C 576
ASP C 564
1.64A14.69
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EBK_A_TOYA301_1
(AMINOGLYCOSIDE
NUCLEOTIDYLTRANSFERA
SE)		6m1d ACE2
(Homo
sapiens)		5 / 9
GLU B 182
GLU B 181
ASP B 499
TYR B 180
ALA B 501
1.76A16.13
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 9
ASP C 445
GLU C 437
SER C 122
SER C 118
ALA C 117
1.73A13.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m1d SODIUM-DEPENDENT
NEUTRAL AMINO ACID
TRANSPORTER B(0)AT1
(Homo
sapiens)		5 / 10
ASP C 445
GLU C 437
SER C 122
SER C 118
ALA C 117
1.71A13.87
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m1d ACE2
(Homo
sapiens)		5 / 10
PHE D 715
ASP B 713
SER B 646
SER D 645
ALA D 648
1.69A12.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 235
TYR A 238
ILE A 466
TYR A 294
1.77A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.60A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m71 NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.58A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.71A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 481
ASP A 477
GLU A 474
ASP A 304
1.73A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 481
ASP A 477
GLU A 474
ASP A 304
1.76A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		4 / 8
ASP H 115
ASP H 113
ILE L  53
ASP L  60
1.51A20.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
HEAVY CHAIN
S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		4 / 8
ASP H 115
ASP H 113
ILE L  53
ASP L  60
1.48A20.68
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6nb8 S230 ANTIGEN-BINDING
(FAB) FRAGMENT,
LIGHT CHAIN
(Homo
sapiens)		5 / 10
PHE L 121
SER L 179
ALA L 116
ASP L 172
THR L 177
1.76A18.27
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6nur NSP12
NSP8
(SARSr-CoV)		4 / 8
TYR A 273
ASP B 112
ILE B 119
ASP A 269
1.33A14.95
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6nus NSP12
(SARSr-CoV)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.57A11.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6nus NSP12
(SARSr-CoV)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.54A11.39
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A  40
TYR A 204
ILE A 197
ASP A  53
1.11A8.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A  40
TYR A 204
ILE A 197
ASP A  53
1.06A8.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLU A1092
SER C1123
ALA C1087
THR C1120
ASP A1118
1.63A9.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.32A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.30A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR A 396
ASN A 394
GLU A 516
ARG A 466
GLY B 232
1.64A9.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_A_TOYA201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
ARG A 466
GLY B 232
TYR A 396
ASN A 394
GLU A 516
1.70A9.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.32A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.39A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE C 429
ASP C 428
ILE L  28
SER C 514
VAL C 512
1.77A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 10
PHE L 116
SER L 174
ALA L 112
ASP L 167
THR L 172
1.78A17.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		5 / 10
PHE L 116
SER L 174
ALA L 111
ASP L 167
THR L 172
1.74A17.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6w41 CR3022 FAB HEAVY
CHAIN
(Homo
sapiens)		4 / 8
TYR H  32
ASP H 101
ILE H  34
TYR H  52
1.66A21.24
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6w4h NSP16
(SARS-CoV-2)		5 / 10
ASN A6975
GLU A6945
ASP A6912
GLY A6953
ASP A6977
1.71A18.73
None
None
SAM  A7102 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w4h NSP16
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.73A20.25
ACT  A7104 (-3.8A)
None
None
None
SAM  A7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
ASN A6975
GLU A6945
ASP A6912
GLY A6953
ASP A6977
1.68A22.41
None
None
SAM  A7104 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.73A
EDO  A7102 (-3.8A)
None
None
None
SAM  A7104 (-2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
TYR C7020
ASP C6942
ILE C7027
TYR C6979
1.54A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w75 NSP16
(SARS-CoV-2)		5 / 10
PHE C6947
SER C6927
ALA C6966
ASP C6895
ASP C6897
1.74A20.90
FMT  C7115 ( 3.5A)
None
None
None
SAM  C7105 ( 2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ASP A6931
GLU A6945
ASP A6942
TYR A7020
1.74A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w75 NSP16
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.72A20.90
SAM  A7102 ( 4.8A)
None
None
None
SAM  A7102 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6w75 NSP16
(SARS-CoV-2)		4 / 8
TYR C7020
ASP C6942
ILE C7027
TYR C6979
1.58A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.73A
SAH  A7102 (-4.7A)
None
None
None
SAH  A7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ASP A6931
GLU A6945
ASP A6942
TYR A7020
1.72A21.82
None
FMT  A7108 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE C6947
SER C6927
ALA C6966
ASP C6895
ASP C6897
1.75A
SAH  C7102 (-4.6A)
None
None
None
SAH  C7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ASP A6931
GLU A6945
ASP A6942
TYR A7020
1.80A21.82
None
FMT  A7108 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wkq NSP16
(SARS-CoV-2)		5 / 10
PHE C6947
SER C6927
ALA C6966
ASP C6895
ASP C6897
1.74A
FMT  C7105 ( 3.5A)
None
None
None
SFG  C7103 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wkq NSP16
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.72A
SFG  A7103 ( 4.8A)
None
None
None
SFG  A7103 ( 2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 9
PHE A 195
SER A 155
VAL A 156
GLU A 327
GLU A 192
1.53A22.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 302
GLU B 211
ILE B 253
TYR B 226
1.67A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 302
GLU A 211
ILE A 253
TYR A 226
1.79A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 302
GLU A 211
ILE A 253
TYR A 226
1.65A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
ASN A6975
GLU A6945
ASP A6912
GLY A6953
ASP A6977
1.65A
None
None
SAH  A7101 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.74A
SAH  A7101 ( 4.8A)
None
None
None
SAH  A7101 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
ASP D 163
ASP D 161
ILE D 132
TYR D 135
1.64A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.58A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP A 389
SER A 383
TYR B  32
GLU E 327
GLU C  61
1.76A20.30
None
DMS  A 905 (-3.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR H  32
ASP H 107
ILE H  34
TYR H  52
1.60A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.66A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR B  32
ASP B 107
ILE B  34
TYR B  52
1.75A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR H  32
ASP H 107
ILE H  34
TYR H  52
1.76A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6yla HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR B  32
ASP B 107
ILE B  34
TYR B  52
1.60A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.64A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.69A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6ym0 HEAVY CHAIN
(Homo
sapiens)		4 / 8
TYR H  32
ASP H 107
ILE H  34
TYR H  52
1.67A18.37
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.68A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.72A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.75A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.76A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
TYR B  32
ASP B 107
ILE B  34
TYR B  52
1.76A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
TYR H  32
ASP H 107
ILE H  34
TYR H  52
1.76A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE A 429
ASP A 428
ILE C  34
SER A 514
VAL A 512
1.66A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.70A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP A 428
ILE C  34
SER A 514
VAL A 512
TYR A 423
1.70A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.66A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE A 429
ASP A 428
ILE C  34
SER A 514
VAL A 512
1.59A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.65A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP A 428
ILE C  34
SER A 514
VAL A 512
TYR A 423
1.65A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
TYR H  32
ASP H 107
ILE H  34
TYR H  52
1.61A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6yor IGG H CHAIN
(Homo
sapiens)		4 / 8
TYR B  32
ASP B 107
ILE B  34
TYR B  52
1.60A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.59A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 221
GLU A  83
ASP A 218
TYR A 217
1.76A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 477
TYR A 746
ASP A 481
ILE A 696
1.75A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP8
(SARS-CoV-2)		4 / 8
ASP B 163
ASP B 161
ILE B 132
TYR B 135
1.67A22.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.79A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 477
TYR A 746
ASP A 481
ILE A 696
1.78A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 221
GLU A  83
ASP A 218
TYR A 217
1.77A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7btf NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.46A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7btf NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASP A 445
ILE A 450
ASP A 452
TYR A 455
1.77A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv1 NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.46A11.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EBK_A_TOYA301_1
(AMINOGLYCOSIDE
NUCLEOTIDYLTRANSFERA
SE)		7bv1 NSP12
(SARS-CoV-2)		5 / 9
GLU A 136
ASP A 161
GLU A 167
GLU A 796
ALA A 797
1.75A14.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.53A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 235
TYR A 238
ILE A 466
TYR A 294
1.64A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
ASP B 163
ASP B 161
ILE B 132
TYR B 135
1.74A19.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 208
TYR A 237
ASP A  36
TYR A 732
1.75A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.66A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 154
GLU A 144
TYR A 149
1.79A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv2 NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.74A11.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.76A
None